Table 1.
The demographic characteristics and clinical effect data of subjects.
| Characteristics | Treatment group (n = 19) | Control group (n = 17) | P value |
|---|---|---|---|
| Gender (male/female) | 11/8 | 10/7 | 0.955 |
| Age (years) | 59.26 ± 6.89 | 59.78 ± 4.81 | 0.797 |
| BMI (kg/m2) | 19.73 ± 2.23 | 19.62 ± 2.00 | 0.878 |
| Leucopenia (events/total) | 6/19 | 11/17 | 0.049 ∗ |
| Thrombocytopenia (events/total) | 2/19 | 7/19 | 0.041 ∗ |
| Liver dysfunction (events/total) | 3/19 | 4/17 | 0.434 |
| Renal dysfunction (events/total) | 2/19 | 3/17 | 0.445 |
| Neurotoxicity (events/total) | 2/19 | 4/17 | 0.276 |
| Gastrointestinal reaction (events/total) | 3/19 | 8/17 | 0.047 ∗ |
| Karnofsky performance status (KPS) | 78.94 ± 6.34 | 73.32 ± 5.98 | 0.011 ∗ |
| Disease control rate (%) | 15.8 | 17.6 | 0.599 |
∗P < 0.05, compared with the control group.